Nannan Kang

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 6

Top Topics

Multidrug Resistant

Metastatic Colorectal Cancer

Top Venues

Pharmaceuticals (Basel, Switzerland)

Drug development research

This page only lists publications with an associated author ORCID identifier.

Publications

Chen Zhao, Yuan Zeng, Nannan Kang, Yu Liu
A new perspective on antiangiogenic antibody drug resistance: Biomarkers, mechanisms, and strategies in malignancies. Drug development research 85 (6) (2024)
Nannan Kang, Jun Ma, Yuling Hu, Rongrong Di, Lei Wang, Xuanling Zhang, Yisheng Lai, Yu Liu
Targeting MutT Homolog 1 (MTH1) for Breast Cancer Suppression by Using a Novel MTH1 Inhibitor MA-24 with Tumor-Selective Toxicity. Pharmaceuticals (Basel, Switzerland) 17 (3) (2024)
Nannan Kang, Jun Ma, Yuling Hu, Rongrong Di, Lei Wang, Xuanling Zhang, Yisheng Lai, Yu Liu
Targeting MutT Homolog 1 (MTH1) for Breast Cancer Suppression by Using a Novel MTH1 Inhibitor MA-24 with Tumor-Selective Toxicity. Pharmaceuticals (Basel, Switzerland) 17 (3) (2024)
Nannan Kang, Jun Ma, Yuling Hu, Rongrong Di, Lei Wang, Xuanling Zhang, Yisheng Lai, Yu Liu
Targeting MutT Homolog 1 (MTH1) for Breast Cancer Suppression by Using a Novel MTH1 Inhibitor MA-24 with Tumor-Selective Toxicity. Pharmaceuticals (Basel, Switzerland) 17 (3) (2024)
Nannan Kang, Buxi Fan, Yao Sun, Peilin Xue, Yu Liu
Novel specific anti-ESM1 antibodies overcome tumor bevacizumab resistance by suppressing angiogenesis and metastasis. Cancer science (2023)
Nannan Kang, Xue Liang, Buxi Fan, Chen Zhao, Beiyu Shen, Xuemei Ji, Yu Liu
Endothelial-Specific Molecule 1 Inhibition Lessens Productive Angiogenesis and Tumor Metastasis to Overcome Bevacizumab Resistance. Cancers 14 (22) (2022)